Logo image of ABSI

ABSCI CORP (ABSI) Stock Price, Quote, News and Overview

NASDAQ:ABSI - Nasdaq - US00091E1091 - Common Stock - Currency: USD

3.13  -0.09 (-2.8%)

After market: 3.13 0 (0%)

ABSI Quote, Performance and Key Statistics

ABSCI CORP

NASDAQ:ABSI (4/25/2025, 8:00:00 PM)

After market: 3.13 0 (0%)

3.13

-0.09 (-2.8%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High6.33
52 Week Low2.01
Market Cap398.61M
Shares127.35M
Float107.84M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-13 2025-05-13/bmo
IPO07-22 2021-07-22


ABSI short term performance overview.The bars show the price performance of ABSI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

ABSI long term performance overview.The bars show the price performance of ABSI in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 100

The current stock price of ABSI is 3.13 USD. In the past month the price increased by 11.39%. In the past year, price decreased by -31.66%.

ABSCI CORP / ABSI Daily stock chart

ABSI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.12 329.14B
AMGN AMGEN INC 14.17 150.99B
GILD GILEAD SCIENCES INC 13.33 128.61B
VRTX VERTEX PHARMACEUTICALS INC 1702.9 126.96B
REGN REGENERON PHARMACEUTICALS 13.2 65.88B
ARGX ARGENX SE - ADR 323.56 37.54B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 32.72B
ONC BEIGENE LTD-ADR N/A 26.39B
BNTX BIONTECH SE-ADR N/A 24.52B
NTRA NATERA INC N/A 20.79B
BIIB BIOGEN INC 7.22 17.39B
SMMT SUMMIT THERAPEUTICS INC N/A 17.30B

About ABSI

Company Profile

ABSI logo image Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 156 full-time employees. The company went IPO on 2021-07-22. The firm combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. The company is developing a diversified portfolio of programs with a focus on cytokine biology. The company has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.

Company Info

ABSCI CORP

18105 Se Mill Plain Blvd

Vancouver Washington WASHINGTON US

CEO: Sean McClain

Employees: 155

Company Website: https://www.absci.com/

Investor Relations: https://investors.absci.com/

Phone: 13609491041

ABSCI CORP / ABSI FAQ

What is the stock price of ABSCI CORP today?

The current stock price of ABSI is 3.13 USD. The price decreased by -2.8% in the last trading session.


What is the ticker symbol for ABSCI CORP stock?

The exchange symbol of ABSCI CORP is ABSI and it is listed on the Nasdaq exchange.


On which exchange is ABSI stock listed?

ABSI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ABSCI CORP stock?

15 analysts have analysed ABSI and the average price target is 9.31 USD. This implies a price increase of 197.36% is expected in the next year compared to the current price of 3.13. Check the ABSCI CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ABSCI CORP worth?

ABSCI CORP (ABSI) has a market capitalization of 398.61M USD. This makes ABSI a Small Cap stock.


How many employees does ABSCI CORP have?

ABSCI CORP (ABSI) currently has 155 employees.


What are the support and resistance levels for ABSCI CORP (ABSI) stock?

ABSCI CORP (ABSI) has a support level at 3.12 and a resistance level at 3.14. Check the full technical report for a detailed analysis of ABSI support and resistance levels.


Is ABSCI CORP (ABSI) expected to grow?

The Revenue of ABSCI CORP (ABSI) is expected to grow by 89.99% in the next year. Check the estimates tab for more information on the ABSI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ABSCI CORP (ABSI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ABSCI CORP (ABSI) stock pay dividends?

ABSI does not pay a dividend.


When does ABSCI CORP (ABSI) report earnings?

ABSCI CORP (ABSI) will report earnings on 2025-05-13, before the market open.


What is the Price/Earnings (PE) ratio of ABSCI CORP (ABSI)?

ABSCI CORP (ABSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.93).


What is the Short Interest ratio of ABSCI CORP (ABSI) stock?

The outstanding short interest for ABSCI CORP (ABSI) is 19.08% of its float. Check the ownership tab for more information on the ABSI short interest.


ABSI Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to ABSI. When comparing the yearly performance of all stocks, ABSI is a bad performer in the overall market: 81.69% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ABSI Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ABSI. The financial health of ABSI is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ABSI Financial Highlights

Over the last trailing twelve months ABSI reported a non-GAAP Earnings per Share(EPS) of -0.93. The EPS increased by 22.76% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.27%
ROE -57.56%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%1.57%
Sales Q2Q%96.75%
EPS 1Y (TTM)22.76%
Revenue 1Y (TTM)-20.71%

ABSI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to ABSI. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of 2.39% and a revenue growth 89.99% for ABSI


Ownership
Inst Owners64.09%
Ins Owners7.68%
Short Float %19.08%
Short Ratio5.14
Analysts
Analysts82.67
Price Target9.31 (197.44%)
EPS Next Y2.39%
Revenue Next Year89.99%